Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Asset Writedowns and Impairment (2024 - 2025)

Historic Asset Writedowns and Impairment for Kymera Therapeutics (KYMR) over the last 2 years, with Q3 2025 value amounting to $3.9 million.

  • Kymera Therapeutics' Asset Writedowns and Impairment changed N/A to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 2172.59%. This contributed to the annual value of $4.9 million for FY2024, which is N/A changed from last year.
  • Per Kymera Therapeutics' latest filing, its Asset Writedowns and Impairment stood at $3.9 million for Q3 2025.
  • Kymera Therapeutics' 5-year Asset Writedowns and Impairment high stood at $4.9 million for Q1 2024, and its period low was $3.9 million during Q3 2025.